Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market.

Stereotaxis CEO David Fischel is scheduled to present at conferences in New York City.

1 report, 1 independent Updated Sep 2
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Stereotaxis CEO David Fischel is scheduled to present at conferences in New York City.

Who's involved

What this event is mainly about
StereotaxisDavid Fischel

Keep exploring

Part of

Stereotaxis received FDA clearance for commercial launch and submitted applications regarding its procedures in the U.S. market. All 2 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireStereotaxis to Present at Upcoming Investor Conferences ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive